Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-comparative randomized phase 2 study of NALIRINOX versus NALIRI in metastatic pancreatic ductal adenocarcinoma
2020-003889-39Phase 2Active
- Sponsor
- Belgian Group of Digestive Oncology
- Start
- Aug 2021
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of nanoliposomal irinotecan in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Belgian Group of Digestive Oncology. Primary endpoint: Progression-free survival rate at day 85. Started Aug 2021; status: active.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2020-003889-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003889-39.